tiprankstipranks
Trending News
More News >
Citius Oncology (CTOR)
NASDAQ:CTOR
US Market

Citius Oncology (CTOR) AI Stock Analysis

Compare
69 Followers

Top Page

CT

Citius Oncology

(NASDAQ:CTOR)

47Neutral
Citius Oncology's stock score reflects significant financial challenges and bearish technical indicators, offset slightly by its low P/E ratio suggesting potential undervaluation. The absence of revenue and consistent net losses underscore a high-risk profile typical of an early-stage pharmaceutical company. Technical indicators point to negative momentum, while the valuation presents a more optimistic perspective due to the low P/E ratio.
Positive Factors
Growth Opportunities
Citius Oncology plans to expand Lymphir's indications to peripheral T cell lymphoma and broader immune oncology, presenting additional growth opportunities.
Market Opportunity
Lymphir is on track to launch in the CTCL market, which is attractive with minimal direct competition, allowing it to potentially gain rapid market share.
Negative Factors
Manufacturing Challenges
Lymphir is a reformulation of Ontak, addressing previous manufacturing issues, indicating past challenges in production.
Market Competition
Lymphir is targeting the IV-targeted therapy segment of the CTCL market, which usually comes after progression on oral systemics and chemotherapies, suggesting competition from established treatments.

Citius Oncology (CTOR) vs. S&P 500 (SPY)

Citius Oncology Business Overview & Revenue Model

Company DescriptionCitius Oncology (CTOR) is a pharmaceutical company operating within the biotechnology and healthcare sectors. The company focuses on the development and commercialization of innovative therapies aimed at treating cancer. Its core products include a pipeline of experimental cancer drugs designed to target various oncological indications, leveraging advanced research and development techniques to improve patient outcomes.
How the Company Makes MoneyCitius Oncology makes money primarily through the research, development, and commercialization of its cancer treatment drugs. The company's revenue streams include licensing agreements, where it partners with other pharmaceutical companies to co-develop or distribute its products, and sales of approved therapies. Additionally, Citius Oncology may receive milestone payments and royalties from partnerships and collaborations with other entities in the healthcare sector. The company's earnings are influenced by the successful clinical trials and regulatory approval of its drug candidates, as well as strategic partnerships that enhance its market reach.

Citius Oncology Financial Statement Overview

Summary
Citius Oncology's financial performance is characterized by consistent net losses and lack of revenue, reflective of its developmental stage. Balance sheet volatility and negative cash flows highlight financial instability and liquidity challenges, necessitating strategic management.
Income Statement
35
Negative
Citius Oncology shows a challenging income situation with consistent net losses over the reported periods. The absence of revenue and gross profit highlights the early-stage nature or restructuring phase of the company. Despite some improvement in EBIT from 2023 to 2024, the overall profitability metrics remain weak, given the negative net income.
Balance Sheet
45
Neutral
The balance sheet reveals high volatility with fluctuating stockholders' equity and liabilities. Although there is a significant increase in assets from 2023 to 2024, the negative equity in some periods and inconsistent asset base pose stability concerns. The absence of debt could indicate cautious financing, but the negative equity ratios in some periods showcase financial vulnerability.
Cash Flow
40
Negative
Cash flow statements show inconsistent operating cash flows and negative free cash flow, indicating liquidity challenges. The reliance on financing activities to support cash flows is evident, but the lack of consistent positive cash flow from operations could hinder growth prospects. The free cash flow growth rate is negative, which poses a risk for future financial health.
Breakdown
TTMSep 2024Sep 2023Sep 2022
Income StatementTotal Revenue
0.000.000.000.00
Gross Profit
0.000.000.000.00
EBIT
0.00-20.57M-12.12M-4.86M
EBITDA
-6.39M-20.57M-12.12M-4.86M
Net Income Common Stockholders
-6.66M-21.15M-12.70M-5.43M
Balance SheetCash, Cash Equivalents and Short-Term Investments
289.18K112.000.000.00
Total Assets
68.19M84.37M47.73M42.69M
Total Debt
0.003.80M0.000.00
Net Debt
-289.18K3.80M0.000.00
Total Liabilities
31.84K38.23M22.20M6.42M
Stockholders Equity
68.16M46.14M25.54M36.27M
Cash FlowFree Cash Flow
-364.06K-4.87M0.000.00
Operating Cash Flow
-364.06K126.35K0.000.00
Investing Cash Flow
-22.55K-5.00M0.000.00
Financing Cash Flow
353.65K4.87M0.000.00

Citius Oncology Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.62
Price Trends
50DMA
0.87
Negative
100DMA
1.02
Negative
200DMA
3.42
Negative
Market Momentum
MACD
-0.05
Negative
RSI
44.29
Neutral
STOCH
36.23
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CTOR, the sentiment is Negative. The current price of 0.62 is below the 20-day moving average (MA) of 0.70, below the 50-day MA of 0.87, and below the 200-day MA of 3.42, indicating a bearish trend. The MACD of -0.05 indicates Negative momentum. The RSI at 44.29 is Neutral, neither overbought nor oversold. The STOCH value of 36.23 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CTOR.

Citius Oncology Risk Analysis

Citius Oncology disclosed 51 risk factors in its most recent earnings report. Citius Oncology reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Citius Oncology Peers Comparison

Overall Rating
UnderperformOutperform
Sector (63)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
70
Outperform
$17.05B10.4210.36%-1.60%39.71%
GSGSK
65
Neutral
$72.44B22.5819.11%4.20%6.28%-47.11%
OGOGN
64
Neutral
$2.74B3.19429.85%10.54%2.24%-16.11%
63
Neutral
$12.07B9.358.15%79.57%12.85%-5.13%
57
Neutral
$5.49B26.95
47
Neutral
$44.43M2.31-34.78%
* Financial Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
CTOR
Citius Oncology
0.66
-10.48
-94.08%
BIIB
Biogen
118.89
-83.10
-41.14%
GSK
GlaxoSmithKline
36.63
-2.68
-6.82%
GRFS
Grifols SA
7.18
0.79
12.36%
OGN
Organon
11.24
-6.32
-35.99%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.